Article

Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production

Department of Chemical and Biomolecular Engineering, Johns Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 09/2009; 106(35):14802-7. DOI: 10.1073/pnas.0905912106
Source: PubMed

ABSTRACT MDCK cells are currently being considered as an alternative to embryonated eggs for influenza virus propagation and hemagglutinin (HA) production intended for vaccine manufacturing. MDCK cells were found suitable for the virus production but their inability to grow in suspension burdens the process of scale up and hence their production capability. Anchorage-dependent MDCK cells were converted to anchorage-independent cells, capable of growing in suspension as a result of transfection with the human siat7e gene (ST6GalNac V). This gene was previously identified as having an important role in cellular adhesion when the transcriptions of genes from anchorage-dependent and anchorage-independent HeLa cells were compared. Unlike the parental MDCK cells, the siat7e-expressing cells were capable of growing in shake flasks as suspension cultures, achieving maximum concentration of 7 x 10(5) cells/mL while keeping close to 100% viability throughout the growth phase. In production experiments, the siat7e-expressing cells were infected with the Influenza B/Victoria/504/2000 strain. It was determined that the cell-derived viruses retained similar antigenic properties as those obtained from egg-derived viruses and their nucleotide sequences were identical. The specific production of hemagglutinin (expressed in hemagglutination units per 10(6) cells) from the siat7e-expressing cells was approximately 20 times higher than the specific production from the parental MDCK cells. If this suspension process scales up, the production potential of HA from 10 L of siat7e-expressing cells at a concentration of 10(6) cells/mL would be equivalent to the amount of HA obtained from 10,000 embryonated eggs.

1 Follower
 · 
90 Views
  • Source
    • "Alternatively, some cellular components may inhibit host protein synthesis during transfection. Targeted engineering of the MDCK and Hela cell lines in order to increase the capability to replicate influenza virus has been described previously (Chu et al., 2009; Furuse et al., 2009; Hossain et al., 2010; Stech et al., 2008; Yang et al., 2010). This may open ways to achieve better transfection and expression efficacy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Current influenza virus vaccines provide protection in part by antibodies induced to the two surface glycoproteins, the hemagglutinin and the neuraminidase. As a result of the continuous antigenic drift of these glycoproteins, a frequent update of the composition of influenza vaccines is required. The search for more conserved viral epitopes which would induce protective immunity against seasonal influenza viruses and eventually also to novel pandemic influenza viruses has a long history. The ectodomain of the Influenza A Virus M2 Protein has been identified as a possible candidate immunization against influenza. The present study describes the expression of cloned M2 gene in MDCK, HeLa, and COS-7 cells, i.e., in three established eukaryotic cell lines. The expression efficiency was demonstrated by immunofluorescent staining of transfected cells by ELISA, by SDS-PAGE-, and by Western blot-analysis. High level of expression was observed in COS-7 cells. Expression in HeLa and MDCK cells was less efficient. The plasmids constructed in this study may, after modifications, be used for the production of a DNA vaccine. Alternatively the expression product could be refined and used as a purified antigen for the vaccine. Thus, the M2 recombinant protein provides an ideal product for further antigenic, biochemical, structural and functional characterization of the protein and for evaluating its potential for immunodiagnosis and in vaccine studies.
    Journal of virological methods 11/2011; 179(1):161-5. DOI:10.1016/j.jviromet.2011.10.016 · 1.88 Impact Factor
  • Source
    • "Influenza pandemics remain a serious public health problem worldwide. Influenza virus-associated illnesses cause an estimated 200,000–500,000 hospital admissions and hundreds of thousands of deaths annually (Simonsen et al., 2000; Suwannakarn et al., 2010; Cox and Subbarao, 2000; Webby and Webster, 2003; Wang et al., 2010; Chu et al., 2009). The emergence of variations in virus strains is one of the principal challenges facing prevention of infection with influenza virus. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Silver nanoparticles have demonstrated efficient inhibitory activities against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). However, the effects of silver nanoparticles against H1N1 influenza A virus remain unexplored. In this study, the interaction of silver nanoparticles with H1N1 influenza A virus was investigated. Silver nanoparticles with mean particle diameters of 10nm were prepared for the hemagglutination inhibition test, the embryo inoculation assay, and the Mosmann-based 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, where these tests were used to determine the inhibitory activity of silver nanoparticles on H1N1 influenza A virus. MDCK cells were used as the infection model. Electron microscopy analysis and flow cytometry assay were used to determine whether silver nanoparticles could reduce H1N1 influenza A virus-induced apoptosis in MDCK cells. This study demonstrates that silver nanoparticles have anti-H1N1 influenza A virus activities. The inhibitory effects of silver nanoparticles on influenza A virus may be a novel clinical strategy for the prevention of influenza virus infection during the early dissemination stage of the virus.
    Journal of virological methods 09/2011; 178(1-2):137-42. DOI:10.1016/j.jviromet.2011.09.003 · 1.88 Impact Factor
  • Source
    • "Many different approaches are available to develop high expressing cell lines for production of influenza virus. For example, the adaptation of adherent cells to grow in suspension cultures with the help of microcarriers or bioinformatics and genetic engineering technologies is a valuable tool for industrial applications due to easy scale-up and high cell density (Chu et al. 2009; Edwards et al. 2009). MDCK-SIAT1 cells which were engineered to express increased level of a-2, 6-linked sialic acid receptor were found to be superior to conventional MDCK cells for isolation of human influenza virus (Oh et al. 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Influenza is a pandemic contagious disease and causes human deaths and huge economic destruction of poultry in the world. In order to control and prevent influenza, mainly type A, influenza vaccine for human and poultry were available since the 1940s and 1920s, respectively. In the development of vaccine production, influenza viruses were cultured originally from chicken embryos to anchorage-dependent cell lines, such as MDCK and Vero. The anchorage-independent lines have also been used to produce influenza virus, such as PER.C6 and engineering modified MDCK and Vero. During the process of influenza vaccine production, the common problem faced by all producers is how to improve the titer of influenza virus. This paper focuses on the developments of cell culture for influenza virus vaccine production, limitations of cell culture, and relative strategies for improvement virus yields in cell-culture systems.
    Applied Microbiology and Biotechnology 11/2010; 89(4):893-902. DOI:10.1007/s00253-010-2973-9 · 3.81 Impact Factor
Show more

Preview

Download
3 Downloads
Available from